International Clinical Trial: Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739485) titled 'Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study' on July 28.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Liu Shu

Condition: Triple -Negative Breast Cancer

Intervention: Drug: Epirubicin and cyclophosphamide followed by paclitaxel oral solution

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: August 30, 2026

Target Sample Size: 30

To know more, visit https://clinicaltrials.gov/study...